tbuckley/cabot-search huggingface dataset:
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
Authors: G. Curigliano, S. Banerjee, A. Cervantes, M.C. Garassino, P. Garrido, N. Girard, J. Haanen, K. Jordan, F. Lordick, J.P. Machiels, O. Michielin, S. Peters, J. Tabernero, J.Y. Douillard, G. Pentheroudakis, A. Addeo, L. Albiges, P.A. Ascierto, S. Banerjee, F. Barlesi, C. Caldas, F. Cardoso, A. Cervantes, I.F. Chaberny, N.I. Cherny, T.K. Choueiri, M.L.K. Chua, C. Criscitiello, G. Curigliano, E. de Azambuja, D. De Ruysscher, E. de Vries, R. Dent, J.Y. Douillard, D. D’Ugo, R. Dziadziuszko, C. Faivre-Finn, E. Felip, M. Garassino, P. Garrido, N. Girard, R. Glynne-Jones, V. Golfinopoulos, J. Haanen, E. Hamilton, P.A. Jänne, K. Jordan, R. Kanesvaran, S.B. Kim, U.G. Liebert, F. Lordick, J.P. Machiels, O. Michielin, T.S.K. Mok, G. Morgan, R. Obermannova, K. Park, A. Passaro, G. Pentheroudakis, S. Peters, M. Reck, R. Salazar Soler, F. Scotté, S. Senan, C. Sessa, E. Smyth, R. Soo, J.C. Soria, J. Spicer, F. Strasser, J. Tabernero, D.S.W. Tan, D. Trapani, E. Van Cutsem, H. van Halteren, P.E. van Schil, G. Veronesi, J. Yang
Journal: Annals of Oncology (2020)
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Authors: Jagoda K. Jasielec, Tadeusz Kubicki, Noopur Raje, Ravi Vij, Donna Reece, Jesus Berdeja, Benjamin A. Derman, Cara A. Rosenbaum, Paul Richardson, Sandeep Gurbuxani, Sarah Major, Brittany Wolfe, Andrew T. Stefka, Leonor Stephens, Kathryn M. Tinari, Tyler Hycner, Alexandra E. Rojek, Dominik Dytfeld, Kent A. Griffith, Todd M. Zimmerman, Andrzej J. Jakubowiak
Journal: Blood (2020)
Assessment of Real-World Use of Behavioral Health Mobile Applications by a Novel Stickiness Metric
Authors: Andrew D. Carlo, Reza Hosseini Ghomi, Brenna N. Renn, Michael A. Strong, Patricia A. Areán
Journal: JAMA Network Open (2020)

This cross-sectional study uses a novel "stickiness" measure to evaluate which mobile applications for smoking cessation, meditation, and other behavioral health areas are associated with long-term engagement.
Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Authors: Erika J. Crosby, Chaitanya R. Acharya, Anthony-Fayez Haddad, Christopher A. Rabiola, Gangjun Lei, Jun-Ping Wei, Xiao-Yi Yang, Tao Wang, Cong-Xiao Liu, Kay U. Wagner, William J. Muller, Lewis A. Chodosh, Gloria Broadwater, Terry Hyslop, Jonathan H. Shepherd, Daniel P. Hollern, Xiaping He, Charles M. Perou, Shengjie Chai, Benjamin K. Ashby, Benjamin G. Vincent, Joshua C. Snyder, Jeremy Force, Michael A. Morse, Herbert K. Lyerly, Zachary C. Hartman
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Despite promising advances in breast cancer immunotherapy, augmenting T-cell infiltration has remained a significant challenge. Although neither individual vaccines nor immune checkpoint blockade (ICB) have had broad success as monotherapies, we hypothesized that targeted vaccination against an oncogenic driver in combination with ICB could direct and enable antitumor immunity in advanced cancers. Experimental Design: Our models of HER2+ breast cancer exhibit molecular signatures that are reflective of advanced human HER2+ breast cancer, with a small numbers of neoepitopes and elevated immunosuppressive markers. Using these, we vaccinated against the oncogenic HER2Δ16 isoform, a nondriver tumor-associated gene (GFP), and specific neoepitopes. We further tested the effect of vaccination or anti–PD-1, alone and in combination. Results: We found that only vaccination targeting HER2Δ16, a driver of oncogenicity and HER2-therapeutic resistance, could elicit significant antitumor responses, while vaccines targeting a nondriver tumor-specific antigen or tumor neoepitopes did not. Vaccine-induced HER2-specific CD8+ T cells were essential for responses, which were more effective early in tumor development. Long-term tumor control of advanced cancers occurred only when HER2Δ16 vaccination was combined with αPD-1. Single-cell RNA sequencing of tumor-infiltrating T cells revealed that while vaccination expanded CD8 T cells, only the combination of vaccine with αPD-1 induced functional gene expression signatures in those CD8 T cells. Furthermore, we show that expanded clones are HER2-reactive, conclusively demonstrating the efficacy of this vaccination strategy in targeting HER2. Conclusions: Combining oncogenic driver targeted vaccines with selective ICB offers a rational paradigm for precision immunotherapy, which we are clinically evaluating in a phase II trial (NCT03632941).
Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID‐19 Pandemic
Authors: Dipti Talaulikar, Ranjana H. Advani, Andrew R. Branagan, Christian Buske, Meletios A. Dimopoulos, Shirley D'Sa, Maria J. Kersten, Veronique Leblond, Monique C. Minnema, Roger G. Owen, Maria Lia Palomba, Alessandra Tedeschi, Judith Trotman, Marzia Varettoni, Josephine M. Vos, Steven P. Treon, Efstathios Kastritis, Jorge J. Castillo
Journal: HemaSphere (2020)

Abstract In the light of the COVID‐19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. We followed the current recommendations by the American Society of Hematology, which have been modified accordingly to fit the specific realities associated with the management of WM. In this Consensus Statement, the Panel addresses questions related to treatment initiation, preferred therapies, minimizing visit to clinics and infusions centers, supportive care and guidance for WM patients in clinical trials. Finally, we also provide information on timing and appropriateness of testing and management of COVID‐19 infected patients, as well as ways to get physicians and patients involved in registry studies that could help others.
The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series
Authors: Naomi Serling-Boyd, Amir M Mohareb, Arthur Y Kim, Emily P Hyle, Zachary S Wallace
Journal: Annals of the Rheumatic Diseases (2020)

The use of immunosuppressive medications in people with hepatitis B virus (HBV) infection is associated with an increased risk of HBV reactivation, which can lead to liver failure and death. Tumour necrosis factor inhibitors, rituximab and other biologic treatments have been associated with HBV reactivation in up to 24% of people with resolved HBV (positive core antibody (HBcAb), negative surface antigen (HBsAg) and positive or negative surface antibody (HBsAb)) and 34% of people with chronic HBV (positive HBsAg); reactivation risk varies based on HBsAb status.1–3 Both tocilizumab (interleukin-6 (IL-6) receptor inhibitor) and tofacitinib (Janus kinase (JAK) inhibitor) interfere with IL-6 signalling, which moderates immune control of chronic HBV. Although HBV reactivation has been reported with tocilizumab and tofacitinib in Asia, limited data describe this risk in the USA.4 

We performed a retrospective study of people who were prescribed tocilizumab or tofacitinib and had resolved or chronic HBV infection between 1995 and 2018 in the Partners Health Care System (PHS).5 We extracted relevant variables from the electronic health record and …
Donald Macgregor Brown
Authors: Iain D M Brown
Journal: BMJ (2020)

Donald Macgregor Brown was a trusted and respected consultant anaesthetist, who spent many devoted years at Glasgow Royal Infirmary. His steadiness and careful appreciation of the individual left his patients with a sense of safety and care delivered by the team. During his time at GRI he developed the chronic pain clinic, a passion for him. He used to joke it was more psychology than anaesthesia, spending lengthy appointments with patients, preparing them for life with pain. For example, Donald developed alternative modes of pain treatment—such as hypnosis—lending an extra dimension to the scope of treatment for patients. This was one of the first such clinics in the UK, and with John Reid he established this ongoing service in the hospital. Donald always saw that as his major achievement, but there were so many others. He worked …
Association of the <i>RPA3-UMAD1</i> locus with interstitial lung diseases complicated with rheumatoid arthritis in Japanese
Authors: Yuya Shirai, Suguru Honda, Katsunori Ikari, Masahiro Kanai, Yoshito Takeda, Yoichiro Kamatani, Takayuki Morisaki, Eiichi Tanaka, Atsushi Kumanogoh, Masayoshi Harigai, Yukinori Okada
Journal: Annals of the Rheumatic Diseases (2020)

Objectives The genetic background of rheumatoid arthritis–interstitial lung disease (RA-ILD) has been evaluated in Europeans, but little knowledge has been obtained in non-Europeans. This study aimed to elucidate genome-wide risk of RA-ILD in non-Europeans. Methods We performed an initial genome-wide association study (GWAS) of RA-ILD in the Japanese population. By conducting the meta-analysis of the three GWAS datasets of the RA cohorts and biobank of Japanese, our study included 358 RA-ILD cases and 4550 RA subjects without ILD. We then conducted the stratified analysis of the effect of the GWAS risk allele in each CT image pattern. Results We identified one novel RA-ILD risk locus at 7p21 that satisfied the genome-wide significance threshold (rs12702634 at RPA3-UMAD1 , OR=2.04, 95% CI 1.59 to 2.60, p=1.5×10 −8 ). Subsequent stratified analysis based on the CT image patterns demonstrated that the effect size of the RA-ILD risk allele (rs12702634-C) was large with the UIP pattern (OR=1.86, 95% CI 0.97 to 3.58, p=0.062) and the probable UIP pattern (OR=2.26, 95% CI 1.36 to 3.73, p=0.0015). Conclusion We revealed one novel genetic association with RA-ILD in Japanese. The RA-ILD risk of the identified variant at RPA3-UMAD1 was relatively high in the CT image patterns related to fibrosis. Our study should contribute to elucidation of the complicated aetiology of RA-ILD.
COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine
Authors: Cheng Lay Teh, Yaw Kiet Cheong, Wan Rosmaiza Wan Musa, Sharifah Aishah Wan Mohd Akbar, Noraini Mat Husin, Suk Chyn Gun
Journal: Annals of the Rheumatic Diseases (2020)

We read with interest the letter by Mathian A et al 1 describing the clinical course of COVID-19 in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. The COVID-19 Global Rheumatology Alliance registry2 shows that 19 (17%) of 110 patients with rheumatic diseases who have been diagnosed with COVID-19 as of 1 April 2020 were patients with lupus. Bozzalla Cassione et al ,3 Romao et al 4 and Ye et al ,5 respectively, described patients with SLE in their papers. The latest paper by D’Silva et al reported ten cases of lupus in their cohort.6 We would like to share the clinical course of COVID-19 among patients with SLE in Malaysia.

As of 30 March 2020, there were five cases of SLE from a total of 2626 cases of COVID-19 in Malaysia. Clinical data were obtained through a review of medical records. COVID-19 was …
Response to: ‘COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine’ by Teh <i>et al</i>
Authors: Alexis Mathian, Zahir Amoura
Journal: Annals of the Rheumatic Diseases (2020)

<b>Background:</b> Many genome-wide scans aimed at complex traits have been statistically underpowered due to small sample size. Combining data from several genome-wide screens with comparable quantitative phenotype data should improve statistical power for the localisation of genomic regions contributing to these traits. <b>Objective:</b> To perform a genome-wide screen for loci affecting adult stature by combined analysis of four previously performed genome-wide scans. <b>Methods:</b> We developed a web based computer tool, Cartographer, for combining genetic marker maps which positions genetic markers accurately using the July 2003 release of the human genome sequence and the deCODE genetic map. Using Cartographer, we combined the primary genotype data from four genome-wide scans and performed variance components (VC) linkage analyses for human stature on the pooled dataset of 1417 individuals from 277 families and performed VC analyses for males and females separately. <b>Results:</b> We found significant linkage to stature on 1p21 (multipoint LOD score 4.25) and suggestive linkages on 9p24 and 18q21 (multipoint LOD scores 2.57 and 2.39, respectively) in males-only analyses. We also found suggestive linkage to 4q35 and 22q13 (multipoint LOD scores 2.18 and 2.85, respectively) when we analysed both females and males and to 13q12 (multipoint LOD score 2.66) in females-only analyses. <b>Conclusions:</b> We strengthened the evidence for linkage to previously reported quantitative trait loci (QTL) for stature and also found significant evidence of a novel male-specific QTL on 1p21. Further investigation of several interesting candidate genes in this region will help towards characterisation of this first sex-specific locus affecting human stature.
Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study
Authors: Jiangwei Xia, Shu-Yang Xie, Ke-Qi Liu, Lin Xu, Pian-Pian Zhao, Si-Rui Gai, Peng-Lin Guan, Jin-Qiu Zhao, Yan-Ping Zhu, Lam C Tsoi, Philip E Stuart, Rajan P Nair, Han-Qi Yang, Yu-Ting Liao, Kaijing Mao, Mo-Chang Qiu, Zhi-Min Ying, Bin Hu, Zhi-Hua Yang, Wei-Yang Bai, Xiao-Wei Zhu, Pei-Kuan Cong, James T Elder, Zhao-Ming Ye, Bin Wang, Hou-Feng Zheng
Journal: Annals of the Rheumatic Diseases (2020)

Objectives and methods With 432 513 samples from UK Biobank dataset, multivariable linear/logistic regression were used to estimate the relationship between psoriasis/psoriatic arthritis (PsA) and estimated bone mineral density (eBMD)/osteoporosis, controlling for potential confounders. Here, confounders were set in three ways: model0 (including age, height, weight, smoking and drinking), model1 (model0 +regular physical activity) and model2 (model1 +medication treatments). The eBMD was derived from heel ultrasound measurement. And 4904 patients with psoriasis and 847 patients with PsA were included in final analysis. Mendelian randomisation (MR) approach was used to evaluate the causal effect between them. Results Lower eBMD were observed in patients with PsA than in controls in both model0 (β-coefficient=−0.014, p=0.0006) and model1 (β-coefficient=−0.013, p=0.002); however, the association disappeared when conditioning on treatment with methotrexate or ciclosporin (model2) (β-coefficient=−0.005, p=0.28), mediation analysis showed that 63% of the intermediary effect on eBMD was mediated by medication treatment (p&lt;2E-16). Patients with psoriasis without arthritis showed no difference of eBMD compared with controls. Similarly, the significance of higher risk of osteopenia in patients with PsA (OR=1.27, p=0.002 in model0) could be eliminated by conditioning on medication treatment (p=0.244 in model2). Psoriasis without arthritis was not related to osteopenia and osteoporosis. The weighted Genetic Risk Score analysis found that genetically determined psoriasis/PsA were not associated with eBMD (p=0.24 and p=0.88). Finally, MR analysis showed that psoriasis/PsA had no causal effect on eBMD, osteoporosis and fracture. Conclusions The effect of PsA on osteoporosis was secondary (eg, medication) but not causal. Under this hypothesis, psoriasis without arthritis was not a risk factor for osteoporosis.
Disparities in outcomes of CD8 <sup>+</sup> cutaneous T‐cell lymphoma by race and presenting lesion location
Authors: F. N. Mirza, S. Yumeen, M. Girardi
Journal: British Journal of Dermatology (2020)

While cutaneous T-cell lymphoma (CTCL) presents most commonly with a CD4+ phenotype, CD8+ and CD30+ variants have also been described. CD8+ variants include primary cutaneous epidermotropic cytotoxic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, cutaneous CD8+ lymphomas associated with immunodeficiency, and CD8+ variants of other well-defined CTCLs1 . While the epidemiology of other CTCLs has been well described, there remains a dearth of literature characterizing the incidence and survival patterns of CD8+ CTCL2 . Thus, we aimed to better characterize data on US national epidemiologic trends of this diverse group of malignancies using the Surveillance, Epidemiology, and End Results (SEER) database.
Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil
Authors: William Marciel de Souza, Lewis Fletcher Buss, Darlan da Silva Candido, Jean-Paul Carrera, Sabrina Li, Alexander E. Zarebski, Rafael Henrique Moraes Pereira, Carlos A. Prete, Andreza Aruska de Souza-Santos, Kris V. Parag, Maria Carolina T. D. Belotti, Maria F. Vincenti-Gonzalez, Janey Messina, Flavia Cristina da Silva Sales, Pamela dos Santos Andrade, Vítor Heloiz Nascimento, Fabio Ghilardi, Leandro Abade, Bernardo Gutierrez, Moritz U. G. Kraemer, Carlos K. V. Braga, Renato Santana Aguiar, Neal Alexander, Philippe Mayaud, Oliver J. Brady, Izabel Marcilio, Nelson Gouveia, Guangdi Li, Adriana Tami, Silvano Barbosa de Oliveira, Victor Bertollo Gomes Porto, Fabiana Ganem, Walquiria Aparecida Ferreira de Almeida, Francieli Fontana Sutile Tardetti Fantinato, Eduardo Marques Macário, Wanderson Kleber de Oliveira, Mauricio L. Nogueira, Oliver G. Pybus, Chieh-Hsi Wu, Julio Croda, Ester C. Sabino, Nuno Rodrigues Faria
Journal: Nature Human Behaviour (2020)
Treating Migraine in Children and Adolescents—Reply
Authors: Boris Zernikow
Journal: JAMA Pediatrics (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
INCREASED RISK OF COLORECTAL CANCER IN PATIENTS TREATED FOR HODGKIN LYMPHOMA: A LONG-TERM FOLLOW-UP STUDY IN THE NETHERLANDS
Authors: A.V. Eggermond, M. Schaapveld, Bruin, G. Ouwens, C. Janus, S. Krol, J. Zijlstra, M. Louwman, B. Aleman, F.V. Leeuwen
Journal: Annals of Oncology (2011)
Targetable Biological Mechanisms Implicated in Emergent Psychiatric Conditions Associated With SARS-CoV-2 Infection
Authors: Teodor T. Postolache, Michael E. Benros, Lisa A. Brenner
Journal: JAMA Psychiatry (2020)

With SARS-CoV-2 InfectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 and then rapidly led to a pandemic with widespread cases of SARS and excess mortality.In response, mitigation efforts (including social distancing, quarantining, and closing of businesses and schools) have resulted in an unprecedented economic downfall.There is concern that these environmental stressors, augmented by psychological factors, such as loss of control, fear of death and dying, and isolation, are contributing to the emergence of psychiatric outcomes of the coronavirus disease 2019 (COVID-19) pandemic. 1Furthermore, coronaviruses may induce cognitive, emotional, neurovegetative, and behavioral dysregulation through biological mechanisms, including direct neuroinvasion and triggering of immune activation.Increasing evidence has linked immune activation with depression and suicidal behavior, and according to several large meta-analyses, anti-inflammatory approaches have demonstrated efficacy in treating depression. 2 Many infections involving hospital contact are predictively associated with suicide, and maximum behavioral effects can take more than 6 months postinfection to fully develop. 3This suggests priming of cellular immune substrates rather than immediate effects.Priming is defined as an alteration (most often enhancement) of subsequent responses by an initial stimulus and involves cellular morphological and physiological changes.Priming by immune activation that is triggered by infection (ie, first hit) may not necessarily induce persistent psychiatric syndromes in itself.Yet it may progressively increase sensitivity to common proinflammatory stimuli (ie, second hit), which include other mild infections, concussions, airborne allergen and pollutant exposure, and psychological stressors.In addition, coronaviruses seem capable of directly invading the central nervous system (CNS) 4,5 via neural and hematogenous routes.The neural pathways involve the transport of the virus to the CNS from the nasal cavity and rhinopharynx via the olfactory and trigeminal nerves and from the lower respiratory tract via the vagus nerves. 4The hematogenous neuroinvasion occurs via the bloodstream and encompasses 3 components dependent on which cell is infected by coronaviruses on their path toward the CNS.These include (1) leukocytes (predominantly monocytes) that serve as a vehicle of dissemination into the CNS, (2) endothelial cells belonging to the blood-brain barrier, or (3) endothelial cells of the blood-cerebrospinal fluid barrier located in the ven-
Amniotic fluid peptides predict postnatal kidney survival in developmental kidney disease
Authors: Julie Klein, Bénédicte Buffin-Meyer, Franck Boizard, Nabila Moussaoui, Ophélie Lescat, Benjamin Breuil, Camille Fedou, Guylène Feuillet, Audrey Casemayou, Eric Neau, An Hindryckx, Luc Decatte, Elena Levtchenko, Anke Raaijmakers, Christophe Vayssière, Valérie Goua, Charlotte Lucas, Franck Perrotin, Sylvie Cloarec, Alexandra Benachi, Marie-Christine Manca-Pellissier, Hélène Laurichesse Delmas, Lucie Bessenay, Claudine Le Vaillant, Emma Allain-Launay, Jean Gondry, Bernard Boudailliez, Elisabeth Simon, Fabienne Prieur, Marie-Pierre Lavocat, Anne-Hélène Saliou, Loic De Parscau, Laurent Bidat, Catherine Noel, Corinne Floch, Guylène Bourdat-Michel, Romain Favre, Anne-Sophie Weingertner, Jean-François Oury, Véronique Baudouin, Jean-Paul Bory, Christine Pietrement, Maryse Fiorenza, Jérôme Massardier, Sylvie Kessler, Nadia Lounis, Françoise Conte Auriol, Pascale Marcorelles, Sophie Collardeau-Frachon, Petra Zürbig, Harald Mischak, Pedro Magalhães, Julie Batut, Patrick Blader, Jean-Sebastien Saulnier Blache, Jean-Loup Bascands, Franz Schaefer, Stéphane Decramer, Joost P. Schanstra, Karel Allegaert, Yves Aubard, Odile Basmaison, Jean-Baptiste Benevent, Florence Biquard, Gérard Champion, Jean-Marie Delbosc, Philippe Eckart, Marie-Françoise Froute, Pascal Gaucherand, Marion Groussolles, Vincent Guigonis, Blandine Hougas, Gwenaelle Le Bouar, Alain Martin, Sophie Martin, Mariannick Maupin-Hyvonnet, Marina Merveille, Eve Mousty, François Nobili, Amelie Ryckewaert, Agnes Sartor, Sophie Taque, Norbert Winer
Journal: Kidney International (2020)
RPS15 mutations and Treatment Outcome in Chronic Lymphocytic Leukemia - Results from the CLL11 Phase III Trial (Chlorambucil (Clb) with or without the Addition of Rituximab (R) or Obinutuzumab (GA101, G)) of the German CLL Study Group
Authors: Sven Estenfelder, Ann-Kathrin Holland-Letz, Eugen Tausch, Sandra Robrecht, Jasmin Bahlo, Valentin Goede, Veronika Opatrna, Matthias Ritgen, Jacques Jm van Dongen, Anton W Langerak, Günter Fingerle-Rowson, Michael Kneba, Kirsten Fischer, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2017)